Fundz

Insight Molecular Diagnostics Inc. reported raising $21.7 Million in an initial SEC Form D filing, from an offering of $21.7 Million

PUBLIC · IMDXFeb 24, 2025

Amount Raised

$21.7 Million

$21.7 Million per company press release (Mar 25, 2025)

Round Type

Venture

IrvineBiotechnologyHealth CareGeneticsHealth Diagnostics

Investors

Bio-Rad Laboratories

Quick answer

Insight Molecular Diagnostics Inc. raised $21.7 Million in a funding round, dated February 10, 2025. Investors: Bio-Rad Laboratories. Insight Molecular Diagnostics Inc. is based in Irvine, California, United States.

How much did Insight Molecular Diagnostics Inc. raise?
Insight Molecular Diagnostics Inc. raised $21.7 Million in a funding round on February 10, 2025.
Who invested in Insight Molecular Diagnostics Inc?
Bio-Rad Laboratories is named as investors in this round.
What does Insight Molecular Diagnostics Inc. do?
Oncocyte™ is a precision diagnostics company with a mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey.
Where is Insight Molecular Diagnostics Inc. based and how big is it?
Insight Molecular Diagnostics Inc. is based in Irvine, California, United States. Fundz records about 56 employees.
Who are the decision-makers at Insight Molecular Diagnostics Inc?
Fundz holds 1 contact at Insight Molecular Diagnostics Inc. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who to call at Insight Molecular Diagnostics Inc., and when

A new round usually means Insight Molecular Diagnostics Inc. is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Insight Molecular Diagnostics Inc. raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Insight Molecular Diagnostics Inc., from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Insight Molecular Diagnostics Inc.. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Insight Molecular Diagnostics Inc.

Location

15 CUSHING

Irvine, California, United States

About

Oncocyte™ is a precision diagnostics company with a mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Insight Molecular Diagnostics Inc. raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contacts10 people are listed at Insight Molecular Diagnos…. We don't have their email yet.See plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Insight Molecular Diagnostics Inc.'s next move

See what Strategic adds

Insight Molecular Diagnostics Inc. raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.